{"gene":"ZSCAN21","run_date":"2026-06-11T09:02:07","timeline":{"discoveries":[{"year":1999,"finding":"Zipro1 (ZSCAN21/Zfp38) promotes proliferation of granule cell precursors in the developing cerebellum and epithelial cells in skin; BAC-mediated gene-dosage increase in transgenic mice caused expanded cerebellar granule cell precursor pools and a hair-loss phenotype with increased epithelial cell proliferation and abnormal hair follicle development.","method":"BAC-mediated transgenic gene-dosage analysis in mice","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic gain-of-function with defined cellular phenotype, single lab, single method (gene dosage transgenic)","pmids":["10431235"],"is_preprint":false},{"year":2006,"finding":"The SCAN domain of NY-REN-21 (ZSCAN21) can form homodimers and also forms a heterodimer with SCAND1 (a truncated SCAN-box protein lacking zinc fingers); the NY-REN-21/SCAND1 heterodimer is asymmetric with respect to DNA binding. The central region of NY-REN-21 behaves as an intrinsically disordered protein.","method":"Yeast two-hybrid, recombinant protein interaction assay, spectroscopic characterization (CD, structural characterization)","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed with recombinant protein pulldown, single lab, two orthogonal methods","pmids":["16540086"],"is_preprint":false},{"year":2009,"finding":"ZSCAN21 binds a site in intron 1 of the SNCA (alpha-synuclein) gene and activates SNCA transcription in PC12 cells; siRNA knockdown of ZSCAN21 inhibits intron 1-driven luciferase activity and reduces SNCA protein levels in naive and neurotrophin-treated PC12 cells and in primary cortical neurons.","method":"Luciferase transcriptional reporter assay, siRNA knockdown, Western blot for SNCA protein","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across cell types (PC12 and primary neurons), multiple orthogonal methods (reporter assay, siRNA, protein quantification), independently replicated in subsequent studies","pmids":["19549071"],"is_preprint":false},{"year":2008,"finding":"Zipro1 (ZSCAN21) mRNA and protein levels increase in non-myelinating Schwann cells of the rat cervical sympathetic trunk following nerve transection, and Zipro1 protein is expressed in terminal Schwann cells and upregulated after skeletal muscle denervation, implicating it in transcriptional reprogramming during Schwann cell activation.","method":"RT-PCR, immunofluorescence/protein expression analysis after nerve transection in rat","journal":"Neuroscience","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, expression-level observation with no functional follow-up demonstrating a mechanism","pmids":["18440155"],"is_preprint":false},{"year":2013,"finding":"ZSCAN21 represses alpha-synuclein expression and simultaneously increases beta-synuclein expression in cells, and ZSCAN21 expression decreases alpha-synuclein aggregation.","method":"Transcription factor overexpression/knockdown, aggregation assay in cell culture","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional gain- and loss-of-function with two phenotypic readouts (gene expression and aggregation), single lab","pmids":["24080388"],"is_preprint":false},{"year":2015,"finding":"ZSCAN21 occupies a region within SNCA intron 1 in human brain tissue, as confirmed by chromatin immunoprecipitation and electrophoretic mobility shift assay (EMSA).","method":"ChIP in human brain tissue, EMSA","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal DNA-binding methods (ChIP in native tissue + EMSA), single lab","pmids":["26002080"],"is_preprint":false},{"year":2016,"finding":"ZSCAN21 binds the intron 1 region of SNCA in rat cortical cultures; lentivirus-mediated silencing of ZSCAN21 increases SNCA promoter activity, mRNA, and protein levels in cortical cultures but reduces SNCA in neurosphere cultures, revealing cell-context-dependent bidirectional regulation. ZSCAN21 overexpression in cortical neurons produces robust mRNA but negligible protein, indicating tight post-transcriptional/post-translational regulation of ZSCAN21 itself. AAV-mediated ZSCAN21 knockdown in postnatal/adult rat hippocampus did not significantly alter SNCA levels in vivo.","method":"ChIP, lentiviral and AAV-mediated shRNA knockdown, luciferase reporter assay, qRT-PCR, Western blot in primary rat neurons and in vivo","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ChIP, lentiviral KD, AAV KD in vivo, reporter, protein quantification) across multiple neuronal models, single lab but rigorous","pmids":["26907683"],"is_preprint":false},{"year":2018,"finding":"TRIM41 is an E3 ubiquitin ligase that ubiquitinates ZSCAN21 and targets it for proteasomal degradation, thereby reducing SNCA transcription. TRIM17 antagonizes TRIM41-mediated degradation of ZSCAN21, thereby stabilizing ZSCAN21 and increasing SNCA expression. Parkinson's disease-associated variants in ZSCAN21 and TRIM41 result in stabilization of the ZSCAN21 protein.","method":"siRNA knockdown, co-immunoprecipitation, ubiquitination assay, qRT-PCR, Western blot; MPTP mouse model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ubiquitination assay, genetic KD with defined molecular and cellular phenotypes, validated in vivo (MPTP mice), multiple orthogonal methods","pmids":["30485814"],"is_preprint":false},{"year":2021,"finding":"ZSCAN21 is identified as a potential reader of 5-formylcytosine (5fC)-modified DNA, based on a proteome-wide TF-DNA modification binding profiling approach.","method":"catTFREs (concatenated tandem array of consensus TF response elements) mass spectrometry-based proteome-wide profiling of 1039 TFs","journal":"Advanced science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single large-scale screen, no specific functional validation of ZSCAN21-5fC interaction reported","pmids":["34351703"],"is_preprint":false},{"year":2025,"finding":"ZSCAN21 stabilization (via reduced TRIM41-mediated ubiquitination) is required for MPP+-triggered transcriptional induction of SNCA in dopaminergic neuronal spheroids; ZSCAN21 knockdown prevents both the increase in alpha-synuclein mRNA/pre-mRNA and the death of dopaminergic neurons in the substantia nigra of MPTP-treated mice. SUMOylation of ZSCAN21 promotes its interaction with TRIM41 and consequent degradation; blocking SUMOylation stabilizes ZSCAN21 and induces SNCA. Parkinson's disease-associated TRIM41 mutations that reduce ZSCAN21-TRIM41 interaction also stabilize ZSCAN21.","method":"shRNA knockdown in LUHMES-derived dopaminergic spheroids, MPTP mouse model with AAV-mediated knockdown, ubiquitination assay, SUMOylation assay, co-immunoprecipitation, qRT-PCR","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (KD in neuronal spheroids, in vivo MPTP mouse KD, ubiquitination, SUMOylation, Co-IP), functional neurodegeneration readout, builds on and replicates prior mechanistic findings","pmids":["40379611"],"is_preprint":false}],"current_model":"ZSCAN21 is a zinc finger/SCAN-domain transcription factor that directly binds intron 1 of the SNCA gene to regulate alpha-synuclein transcription in neurons; its stability and activity are controlled by a TRIM17/TRIM41/SUMOylation axis in which TRIM41-mediated ubiquitination targets ZSCAN21 for proteasomal degradation while TRIM17 antagonizes this, and SUMOylation of ZSCAN21 facilitates its TRIM41-dependent degradation; in Parkinson's disease contexts, ZSCAN21 stabilization drives pathogenic SNCA induction and dopaminergic neuron death. ZSCAN21 can also form homo- and heterodimers (with SCAND1) via its SCAN domain, potentially broadening the set of genes it regulates."},"narrative":{"mechanistic_narrative":"ZSCAN21 is a SCAN-domain, zinc-finger transcription factor that controls neuronal gene expression and cell proliferation, most prominently as a direct regulator of the alpha-synuclein gene SNCA [PMID:19549071, PMID:26907683]. It binds a regulatory site within SNCA intron 1, demonstrated by reporter assays, ChIP in human brain tissue, and EMSA, and modulates SNCA transcription in a cell-context-dependent manner—activating SNCA in PC12 cells and reducing it upon knockdown, while exerting bidirectional effects across cortical versus neurosphere models [PMID:19549071, PMID:26002080, PMID:26907683]. ZSCAN21 protein abundance is tightly post-translationally controlled: the E3 ubiquitin ligase TRIM41 ubiquitinates ZSCAN21 to drive its proteasomal degradation and thereby lower SNCA transcription, whereas TRIM17 antagonizes this degradation to stabilize ZSCAN21 and raise SNCA expression [PMID:30485814]. SUMOylation of ZSCAN21 promotes its interaction with TRIM41 and consequent degradation, so blocking SUMOylation stabilizes the protein and induces SNCA [PMID:40379611]. This stability axis is disease-relevant: Parkinson's disease-associated variants in ZSCAN21 and TRIM41 stabilize ZSCAN21, and in MPP+/MPTP models ZSCAN21 stabilization is required for pathogenic SNCA induction and dopaminergic neuron death, with ZSCAN21 knockdown preventing both [PMID:30485814, PMID:40379611]. Through its SCAN domain ZSCAN21 forms homodimers and an asymmetric heterodimer with the zinc-finger-lacking SCAN protein SCAND1, while its central region is intrinsically disordered [PMID:16540086]. Beyond the nervous system, gene-dosage gain of ZSCAN21 promotes proliferation of cerebellar granule cell precursors and skin epithelial cells [PMID:10431235].","teleology":[{"year":1999,"claim":"Established a cellular role for ZSCAN21 by showing it drives precursor proliferation, addressing whether the factor has developmental growth-promoting activity.","evidence":"BAC-mediated transgenic gene-dosage analysis in mice","pmids":["10431235"],"confidence":"Medium","gaps":["No direct transcriptional targets identified to explain the proliferative phenotype","Gain-of-function only; loss-of-function consequences untested"]},{"year":2006,"claim":"Defined the protein architecture by showing the SCAN domain mediates homo- and SCAND1 heterodimerization and that the central region is disordered, framing how ZSCAN21 might assemble distinct DNA-binding complexes.","evidence":"Yeast two-hybrid, recombinant protein pulldown, and CD/spectroscopic characterization","pmids":["16540086"],"confidence":"Medium","gaps":["Functional consequence of SCAND1 heterodimerization on target-gene regulation untested","No structure of the full-length protein or DNA-bound complex"]},{"year":2009,"claim":"Identified the first defined target gene, showing ZSCAN21 binds SNCA intron 1 and controls alpha-synuclein levels, establishing it as an SNCA regulator.","evidence":"Luciferase reporter, siRNA knockdown, and Western blot in PC12 cells and primary cortical neurons","pmids":["19549071"],"confidence":"High","gaps":["Direct genomic binding in native tissue not yet shown at this stage","Direction of regulation across cell types not resolved"]},{"year":2008,"claim":"Linked ZSCAN21 to injury-responsive transcriptional reprogramming by documenting its upregulation in activated Schwann cells, though without mechanistic targets.","evidence":"RT-PCR and immunofluorescence after nerve transection in rat","pmids":["18440155"],"confidence":"Low","gaps":["Single lab, expression-level observation with no functional follow-up","No target genes or causal role demonstrated"]},{"year":2013,"claim":"Extended ZSCAN21's regulatory output by showing it can repress alpha-synuclein, raise beta-synuclein, and reduce aggregation, hinting at context-dependent and bidirectional control.","evidence":"Overexpression/knockdown and aggregation assays in cell culture","pmids":["24080388"],"confidence":"Medium","gaps":["Opposite directionality versus earlier activation report unexplained at this stage","Mechanism connecting expression change to aggregation unclear"]},{"year":2015,"claim":"Confirmed physiological binding by demonstrating ZSCAN21 occupancy of SNCA intron 1 in human brain, moving the interaction from reporter systems to native chromatin.","evidence":"ChIP in human brain tissue and EMSA","pmids":["26002080"],"confidence":"Medium","gaps":["Functional consequence of occupancy in human tissue not directly tested","Single lab"]},{"year":2016,"claim":"Resolved the regulatory complexity by showing ZSCAN21 acts bidirectionally on SNCA depending on cell context and that ZSCAN21 itself is under tight post-transcriptional/post-translational control, foreshadowing its regulated turnover.","evidence":"ChIP, lentiviral and AAV shRNA knockdown, reporter, qRT-PCR, Western blot in rat neurons and in vivo","pmids":["26907683"],"confidence":"High","gaps":["Mechanism underlying robust mRNA but negligible protein not yet defined","In vivo knockdown in adult hippocampus showed no SNCA change, leaving context dependence unexplained"]},{"year":2018,"claim":"Identified the post-translational control mechanism by showing TRIM41 ubiquitinates ZSCAN21 for degradation while TRIM17 antagonizes it, and tied this stability axis to Parkinson's disease variants.","evidence":"Reciprocal Co-IP, ubiquitination assay, siRNA, qRT-PCR/Western blot, and MPTP mouse model","pmids":["30485814"],"confidence":"High","gaps":["Signal triggering TRIM41 versus TRIM17 balance not defined","How disease variants mechanistically resist degradation not fully resolved"]},{"year":2021,"claim":"Raised the possibility that ZSCAN21 reads DNA modifications by flagging it as a candidate 5-formylcytosine binder in a proteome-wide screen.","evidence":"catTFRE mass spectrometry profiling of 1039 transcription factors","pmids":["34351703"],"confidence":"Low","gaps":["No specific functional validation of a ZSCAN21-5fC interaction","Biological relevance to SNCA regulation untested"]},{"year":2025,"claim":"Completed the disease mechanism by showing SUMOylation drives TRIM41 binding and degradation, and that ZSCAN21 stabilization is required for MPP+/MPTP-triggered SNCA induction and dopaminergic neuron death.","evidence":"shRNA in LUHMES dopaminergic spheroids, AAV knockdown in MPTP mice, ubiquitination, SUMOylation, and Co-IP assays","pmids":["40379611"],"confidence":"High","gaps":["Upstream signals regulating ZSCAN21 SUMOylation not identified","Whether targeting this axis is therapeutically tractable untested"]},{"year":null,"claim":"It remains unknown how ZSCAN21 chooses between activating and repressing SNCA across cell contexts and whether its SCAND1 dimerization or putative 5fC reading broadens its target repertoire beyond SNCA.","evidence":"","pmids":[],"confidence":"Low","gaps":["Genome-wide target landscape not mapped","Determinants of bidirectional regulation undefined","Functional role of SCAND1 heterodimers in gene regulation untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,4,6]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[5,6]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,6]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,9]}],"complexes":[],"partners":["TRIM41","TRIM17","SCAND1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y5A6","full_name":"Zinc finger and SCAN domain-containing protein 21","aliases":["Renal carcinoma antigen NY-REN-21","Zinc finger protein 38 homolog","Zfp-38"],"length_aa":473,"mass_kda":53.7,"function":"Strong transcriptional activator (By similarity). Plays an important role in spermatogenesis; essential for the progression of meiotic prophase I in spermatocytes (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9Y5A6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZSCAN21","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ZSCAN21","total_profiled":1310},"omim":[{"mim_id":"601261","title":"ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 21; ZSCAN21","url":"https://www.omim.org/entry/601261"},{"mim_id":"163890","title":"SYNUCLEIN, ALPHA; SNCA","url":"https://www.omim.org/entry/163890"},{"mim_id":"137295","title":"GATA-BINDING PROTEIN 2; GATA2","url":"https://www.omim.org/entry/137295"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZSCAN21"},"hgnc":{"alias_symbol":["DKFZp434L134","NY-REN-21","Zipro1"],"prev_symbol":["ZNF38"]},"alphafold":{"accession":"Q9Y5A6","domains":[{"cath_id":"1.10.4020.10","chopping":"40-117","consensus_level":"high","plddt":83.9685,"start":40,"end":117}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5A6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5A6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5A6-F1-predicted_aligned_error_v6.png","plddt_mean":65.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZSCAN21","jax_strain_url":"https://www.jax.org/strain/search?query=ZSCAN21"},"sequence":{"accession":"Q9Y5A6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y5A6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y5A6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5A6"}},"corpus_meta":[{"pmid":"10431235","id":"PMC_10431235","title":"BAC-mediated gene-dosage analysis reveals a role for Zipro1 (Ru49/Zfp38) in progenitor cell proliferation in cerebellum and skin.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10431235","citation_count":100,"is_preprint":false},{"pmid":"16406324","id":"PMC_16406324","title":"Generation of cerebellar neuron precursors from embryonic stem cells.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16406324","citation_count":86,"is_preprint":false},{"pmid":"34148545","id":"PMC_34148545","title":"Identification of sixteen novel candidate genes for late onset Parkinson's disease.","date":"2021","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/34148545","citation_count":70,"is_preprint":false},{"pmid":"19549071","id":"PMC_19549071","title":"Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19549071","citation_count":52,"is_preprint":false},{"pmid":"30485814","id":"PMC_30485814","title":"The E3 Ubiquitin Ligases TRIM17 and TRIM41 Modulate α-Synuclein Expression by Regulating ZSCAN21.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30485814","citation_count":35,"is_preprint":false},{"pmid":"16540086","id":"PMC_16540086","title":"Spectroscopic characterization of the tumor antigen NY-REN-21 and identification of heterodimer formation with SCAND1.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16540086","citation_count":33,"is_preprint":false},{"pmid":"26002080","id":"PMC_26002080","title":"Transcriptional regulation of the α-synuclein gene in human brain tissue.","date":"2015","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/26002080","citation_count":23,"is_preprint":false},{"pmid":"36811231","id":"PMC_36811231","title":"Obesity impacts the expression of Alzheimer's disease-related genes: The Framingham Heart Study.","date":"2023","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/36811231","citation_count":22,"is_preprint":false},{"pmid":"24080388","id":"PMC_24080388","title":"Counter-regulation of alpha- and beta-synuclein expression at the transcriptional level.","date":"2013","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/24080388","citation_count":19,"is_preprint":false},{"pmid":"26907683","id":"PMC_26907683","title":"Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26907683","citation_count":18,"is_preprint":false},{"pmid":"34351703","id":"PMC_34351703","title":"Proteome-Wide Profiling of Readers for DNA Modification.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34351703","citation_count":15,"is_preprint":false},{"pmid":"18440155","id":"PMC_18440155","title":"Induction of zinc-finger proliferation 1 expression in non-myelinating Schwann cells after denervation.","date":"2008","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18440155","citation_count":8,"is_preprint":false},{"pmid":"17980864","id":"PMC_17980864","title":"Characterization of a cerebellar granule progenitor cell line, EtC.1, and its responsiveness to 17-beta-estradiol.","date":"2007","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17980864","citation_count":7,"is_preprint":false},{"pmid":"16352405","id":"PMC_16352405","title":"Host cell targets of immediate-early protein BICP22 of bovine herpesvirus 1.","date":"2005","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16352405","citation_count":5,"is_preprint":false},{"pmid":"21951847","id":"PMC_21951847","title":"Cysteine 397 plays important roles in the folding of the neuron-restricted silencer factor/RE1-silencing transcription factor.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21951847","citation_count":5,"is_preprint":false},{"pmid":"40379611","id":"PMC_40379611","title":"ZSCAN21 mediates the pathogenic transcriptional induction of α-synuclein in cellular and animal models of Parkinson's disease.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40379611","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9440,"output_tokens":2622,"usd":0.033825,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9941,"output_tokens":3321,"usd":0.066365,"stage2_stop_reason":"end_turn"},"total_usd":0.10019,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Zipro1 (ZSCAN21/Zfp38) promotes proliferation of granule cell precursors in the developing cerebellum and epithelial cells in skin; BAC-mediated gene-dosage increase in transgenic mice caused expanded cerebellar granule cell precursor pools and a hair-loss phenotype with increased epithelial cell proliferation and abnormal hair follicle development.\",\n      \"method\": \"BAC-mediated transgenic gene-dosage analysis in mice\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic gain-of-function with defined cellular phenotype, single lab, single method (gene dosage transgenic)\",\n      \"pmids\": [\"10431235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The SCAN domain of NY-REN-21 (ZSCAN21) can form homodimers and also forms a heterodimer with SCAND1 (a truncated SCAN-box protein lacking zinc fingers); the NY-REN-21/SCAND1 heterodimer is asymmetric with respect to DNA binding. The central region of NY-REN-21 behaves as an intrinsically disordered protein.\",\n      \"method\": \"Yeast two-hybrid, recombinant protein interaction assay, spectroscopic characterization (CD, structural characterization)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed with recombinant protein pulldown, single lab, two orthogonal methods\",\n      \"pmids\": [\"16540086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZSCAN21 binds a site in intron 1 of the SNCA (alpha-synuclein) gene and activates SNCA transcription in PC12 cells; siRNA knockdown of ZSCAN21 inhibits intron 1-driven luciferase activity and reduces SNCA protein levels in naive and neurotrophin-treated PC12 cells and in primary cortical neurons.\",\n      \"method\": \"Luciferase transcriptional reporter assay, siRNA knockdown, Western blot for SNCA protein\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across cell types (PC12 and primary neurons), multiple orthogonal methods (reporter assay, siRNA, protein quantification), independently replicated in subsequent studies\",\n      \"pmids\": [\"19549071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Zipro1 (ZSCAN21) mRNA and protein levels increase in non-myelinating Schwann cells of the rat cervical sympathetic trunk following nerve transection, and Zipro1 protein is expressed in terminal Schwann cells and upregulated after skeletal muscle denervation, implicating it in transcriptional reprogramming during Schwann cell activation.\",\n      \"method\": \"RT-PCR, immunofluorescence/protein expression analysis after nerve transection in rat\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, expression-level observation with no functional follow-up demonstrating a mechanism\",\n      \"pmids\": [\"18440155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ZSCAN21 represses alpha-synuclein expression and simultaneously increases beta-synuclein expression in cells, and ZSCAN21 expression decreases alpha-synuclein aggregation.\",\n      \"method\": \"Transcription factor overexpression/knockdown, aggregation assay in cell culture\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional gain- and loss-of-function with two phenotypic readouts (gene expression and aggregation), single lab\",\n      \"pmids\": [\"24080388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZSCAN21 occupies a region within SNCA intron 1 in human brain tissue, as confirmed by chromatin immunoprecipitation and electrophoretic mobility shift assay (EMSA).\",\n      \"method\": \"ChIP in human brain tissue, EMSA\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal DNA-binding methods (ChIP in native tissue + EMSA), single lab\",\n      \"pmids\": [\"26002080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZSCAN21 binds the intron 1 region of SNCA in rat cortical cultures; lentivirus-mediated silencing of ZSCAN21 increases SNCA promoter activity, mRNA, and protein levels in cortical cultures but reduces SNCA in neurosphere cultures, revealing cell-context-dependent bidirectional regulation. ZSCAN21 overexpression in cortical neurons produces robust mRNA but negligible protein, indicating tight post-transcriptional/post-translational regulation of ZSCAN21 itself. AAV-mediated ZSCAN21 knockdown in postnatal/adult rat hippocampus did not significantly alter SNCA levels in vivo.\",\n      \"method\": \"ChIP, lentiviral and AAV-mediated shRNA knockdown, luciferase reporter assay, qRT-PCR, Western blot in primary rat neurons and in vivo\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ChIP, lentiviral KD, AAV KD in vivo, reporter, protein quantification) across multiple neuronal models, single lab but rigorous\",\n      \"pmids\": [\"26907683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRIM41 is an E3 ubiquitin ligase that ubiquitinates ZSCAN21 and targets it for proteasomal degradation, thereby reducing SNCA transcription. TRIM17 antagonizes TRIM41-mediated degradation of ZSCAN21, thereby stabilizing ZSCAN21 and increasing SNCA expression. Parkinson's disease-associated variants in ZSCAN21 and TRIM41 result in stabilization of the ZSCAN21 protein.\",\n      \"method\": \"siRNA knockdown, co-immunoprecipitation, ubiquitination assay, qRT-PCR, Western blot; MPTP mouse model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ubiquitination assay, genetic KD with defined molecular and cellular phenotypes, validated in vivo (MPTP mice), multiple orthogonal methods\",\n      \"pmids\": [\"30485814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZSCAN21 is identified as a potential reader of 5-formylcytosine (5fC)-modified DNA, based on a proteome-wide TF-DNA modification binding profiling approach.\",\n      \"method\": \"catTFREs (concatenated tandem array of consensus TF response elements) mass spectrometry-based proteome-wide profiling of 1039 TFs\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single large-scale screen, no specific functional validation of ZSCAN21-5fC interaction reported\",\n      \"pmids\": [\"34351703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZSCAN21 stabilization (via reduced TRIM41-mediated ubiquitination) is required for MPP+-triggered transcriptional induction of SNCA in dopaminergic neuronal spheroids; ZSCAN21 knockdown prevents both the increase in alpha-synuclein mRNA/pre-mRNA and the death of dopaminergic neurons in the substantia nigra of MPTP-treated mice. SUMOylation of ZSCAN21 promotes its interaction with TRIM41 and consequent degradation; blocking SUMOylation stabilizes ZSCAN21 and induces SNCA. Parkinson's disease-associated TRIM41 mutations that reduce ZSCAN21-TRIM41 interaction also stabilize ZSCAN21.\",\n      \"method\": \"shRNA knockdown in LUHMES-derived dopaminergic spheroids, MPTP mouse model with AAV-mediated knockdown, ubiquitination assay, SUMOylation assay, co-immunoprecipitation, qRT-PCR\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (KD in neuronal spheroids, in vivo MPTP mouse KD, ubiquitination, SUMOylation, Co-IP), functional neurodegeneration readout, builds on and replicates prior mechanistic findings\",\n      \"pmids\": [\"40379611\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZSCAN21 is a zinc finger/SCAN-domain transcription factor that directly binds intron 1 of the SNCA gene to regulate alpha-synuclein transcription in neurons; its stability and activity are controlled by a TRIM17/TRIM41/SUMOylation axis in which TRIM41-mediated ubiquitination targets ZSCAN21 for proteasomal degradation while TRIM17 antagonizes this, and SUMOylation of ZSCAN21 facilitates its TRIM41-dependent degradation; in Parkinson's disease contexts, ZSCAN21 stabilization drives pathogenic SNCA induction and dopaminergic neuron death. ZSCAN21 can also form homo- and heterodimers (with SCAND1) via its SCAN domain, potentially broadening the set of genes it regulates.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZSCAN21 is a SCAN-domain, zinc-finger transcription factor that controls neuronal gene expression and cell proliferation, most prominently as a direct regulator of the alpha-synuclein gene SNCA [#2, #6]. It binds a regulatory site within SNCA intron 1, demonstrated by reporter assays, ChIP in human brain tissue, and EMSA, and modulates SNCA transcription in a cell-context-dependent manner—activating SNCA in PC12 cells and reducing it upon knockdown, while exerting bidirectional effects across cortical versus neurosphere models [#2, #5, #6]. ZSCAN21 protein abundance is tightly post-translationally controlled: the E3 ubiquitin ligase TRIM41 ubiquitinates ZSCAN21 to drive its proteasomal degradation and thereby lower SNCA transcription, whereas TRIM17 antagonizes this degradation to stabilize ZSCAN21 and raise SNCA expression [#7]. SUMOylation of ZSCAN21 promotes its interaction with TRIM41 and consequent degradation, so blocking SUMOylation stabilizes the protein and induces SNCA [#9]. This stability axis is disease-relevant: Parkinson's disease-associated variants in ZSCAN21 and TRIM41 stabilize ZSCAN21, and in MPP+/MPTP models ZSCAN21 stabilization is required for pathogenic SNCA induction and dopaminergic neuron death, with ZSCAN21 knockdown preventing both [#7, #9]. Through its SCAN domain ZSCAN21 forms homodimers and an asymmetric heterodimer with the zinc-finger-lacking SCAN protein SCAND1, while its central region is intrinsically disordered [#1]. Beyond the nervous system, gene-dosage gain of ZSCAN21 promotes proliferation of cerebellar granule cell precursors and skin epithelial cells [#0].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established a cellular role for ZSCAN21 by showing it drives precursor proliferation, addressing whether the factor has developmental growth-promoting activity.\",\n      \"evidence\": \"BAC-mediated transgenic gene-dosage analysis in mice\",\n      \"pmids\": [\"10431235\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct transcriptional targets identified to explain the proliferative phenotype\", \"Gain-of-function only; loss-of-function consequences untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the protein architecture by showing the SCAN domain mediates homo- and SCAND1 heterodimerization and that the central region is disordered, framing how ZSCAN21 might assemble distinct DNA-binding complexes.\",\n      \"evidence\": \"Yeast two-hybrid, recombinant protein pulldown, and CD/spectroscopic characterization\",\n      \"pmids\": [\"16540086\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of SCAND1 heterodimerization on target-gene regulation untested\", \"No structure of the full-length protein or DNA-bound complex\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified the first defined target gene, showing ZSCAN21 binds SNCA intron 1 and controls alpha-synuclein levels, establishing it as an SNCA regulator.\",\n      \"evidence\": \"Luciferase reporter, siRNA knockdown, and Western blot in PC12 cells and primary cortical neurons\",\n      \"pmids\": [\"19549071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct genomic binding in native tissue not yet shown at this stage\", \"Direction of regulation across cell types not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked ZSCAN21 to injury-responsive transcriptional reprogramming by documenting its upregulation in activated Schwann cells, though without mechanistic targets.\",\n      \"evidence\": \"RT-PCR and immunofluorescence after nerve transection in rat\",\n      \"pmids\": [\"18440155\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single lab, expression-level observation with no functional follow-up\", \"No target genes or causal role demonstrated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended ZSCAN21's regulatory output by showing it can repress alpha-synuclein, raise beta-synuclein, and reduce aggregation, hinting at context-dependent and bidirectional control.\",\n      \"evidence\": \"Overexpression/knockdown and aggregation assays in cell culture\",\n      \"pmids\": [\"24080388\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Opposite directionality versus earlier activation report unexplained at this stage\", \"Mechanism connecting expression change to aggregation unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Confirmed physiological binding by demonstrating ZSCAN21 occupancy of SNCA intron 1 in human brain, moving the interaction from reporter systems to native chromatin.\",\n      \"evidence\": \"ChIP in human brain tissue and EMSA\",\n      \"pmids\": [\"26002080\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of occupancy in human tissue not directly tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved the regulatory complexity by showing ZSCAN21 acts bidirectionally on SNCA depending on cell context and that ZSCAN21 itself is under tight post-transcriptional/post-translational control, foreshadowing its regulated turnover.\",\n      \"evidence\": \"ChIP, lentiviral and AAV shRNA knockdown, reporter, qRT-PCR, Western blot in rat neurons and in vivo\",\n      \"pmids\": [\"26907683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism underlying robust mRNA but negligible protein not yet defined\", \"In vivo knockdown in adult hippocampus showed no SNCA change, leaving context dependence unexplained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified the post-translational control mechanism by showing TRIM41 ubiquitinates ZSCAN21 for degradation while TRIM17 antagonizes it, and tied this stability axis to Parkinson's disease variants.\",\n      \"evidence\": \"Reciprocal Co-IP, ubiquitination assay, siRNA, qRT-PCR/Western blot, and MPTP mouse model\",\n      \"pmids\": [\"30485814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal triggering TRIM41 versus TRIM17 balance not defined\", \"How disease variants mechanistically resist degradation not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Raised the possibility that ZSCAN21 reads DNA modifications by flagging it as a candidate 5-formylcytosine binder in a proteome-wide screen.\",\n      \"evidence\": \"catTFRE mass spectrometry profiling of 1039 transcription factors\",\n      \"pmids\": [\"34351703\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No specific functional validation of a ZSCAN21-5fC interaction\", \"Biological relevance to SNCA regulation untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Completed the disease mechanism by showing SUMOylation drives TRIM41 binding and degradation, and that ZSCAN21 stabilization is required for MPP+/MPTP-triggered SNCA induction and dopaminergic neuron death.\",\n      \"evidence\": \"shRNA in LUHMES dopaminergic spheroids, AAV knockdown in MPTP mice, ubiquitination, SUMOylation, and Co-IP assays\",\n      \"pmids\": [\"40379611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals regulating ZSCAN21 SUMOylation not identified\", \"Whether targeting this axis is therapeutically tractable untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how ZSCAN21 chooses between activating and repressing SNCA across cell contexts and whether its SCAND1 dimerization or putative 5fC reading broadens its target repertoire beyond SNCA.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Genome-wide target landscape not mapped\", \"Determinants of bidirectional regulation undefined\", \"Functional role of SCAND1 heterodimers in gene regulation untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 4, 6]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TRIM41\", \"TRIM17\", \"SCAND1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}